Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -319.09M | -269.70M | -278.16M | -332.26M | -72.94M |
| Total Depreciation and Amortization | 34.84M | 35.90M | 35.01M | 36.55M | 33.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 479.16M | 487.57M | 425.13M | 415.05M | 480.14M |
| Change in Net Operating Assets | -210.45M | -298.88M | -190.29M | -62.79M | -67.99M |
| Cash from Operations | -15.54M | -45.11M | -8.31M | 56.56M | 372.26M |
| Capital Expenditure | -36.55M | -30.27M | -34.28M | -40.49M | -53.39M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -74.22M | 94.82M | -82.56M | -264.09M | -231.71M |
| Cash from Investing | -110.77M | 64.55M | -116.84M | -304.59M | -285.10M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 274.90M | 326.46M | 302.95M | 297.57M | 214.34M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -43.31M | -17.13M | -8.79M | 4.82M | 18.44M |
| Cash from Financing | 231.59M | 309.33M | 294.16M | 302.39M | 232.77M |
| Foreign Exchange rate Adjustments | 39.39M | 8.76M | -15.24M | 12.93M | -8.72M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.67M | 337.53M | 153.77M | 67.29M | 311.22M |